Discontinued — last reported Q4 '25
OPSUMIT — Sales to Customers
Johnson & Johnson OPSUMIT — Sales to Customers remained flat by 0.0% to $581.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.7%, from $545.00M to $581.25M. Over 4 years (FY 2021 to FY 2025), OPSUMIT — Sales to Customers shows an upward trend with a 6.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption or successful commercial execution for this specific therapy, while a decrease may signal increased competition, patent expiration, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total net revenue generated from the sale of OPSUMIT, a specialized pharmaceutical product us...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or specialized therapeutic assets reported by other large-cap pharmaceutical companies.
jnj_segment_opsumit_sales_to_customersHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $463.00M | $458.00M | $448.00M | $443.00M | $438.00M | $441.00M | $461.00M | $440.00M | $507.00M | $490.00M | $536.00M | $524.00M | $544.00M | $571.00M | $545.00M | $581.25M | $581.25M | $581.25M | $581.25M |
| QoQ Change | — | -1.1% | -2.2% | -1.1% | -1.1% | +0.7% | +4.5% | -4.6% | +15.2% | -3.4% | +9.4% | -2.2% | +3.8% | +5.0% | -4.6% | +6.7% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | -5.4% | -3.7% | +2.9% | -0.7% | +15.8% | +11.1% | +16.3% | +19.1% | +7.3% | +16.5% | +1.7% | +10.9% | +6.8% | +1.8% | +6.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's opsumit — sales to customers?
- Johnson & Johnson (JNJ) reported opsumit — sales to customers of $581.25M in Q4 2025.
- How has Johnson & Johnson's opsumit — sales to customers changed year-over-year?
- Johnson & Johnson's opsumit — sales to customers increased by 6.7% year-over-year, from $545.00M to $581.25M.
- What is the long-term trend for Johnson & Johnson's opsumit — sales to customers?
- Over 4 years (2021 to 2025), Johnson & Johnson's opsumit — sales to customers has grown at a 6.3% compound annual growth rate (CAGR), from $1.82B to $2.33B.
- What does opsumit — sales to customers mean?
- The total revenue generated from sales of the pulmonary arterial hypertension medication OPSUMIT.